Here, we discovered that targeting cell cycle processes or protein ubiquitination pathways are promising treatment strategies for overcoming resistance to EGFR inhibitors in lung cancer using a genome‐scale CRISPR‐Cas9 screening. The gene discussed is EGFR; the disease is lung carcinoma.